The company intends to use the funds to: Support ongoing clinical trials of ANPD001, its lead autologous cell therapy candidate for Parkinson's disease. Scale manufacturing capabilities to meet clinical and future commercial demand. Advance its pipeline of autologous iPSC-derived therapies for additional neurological indications.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

10835 Rd. to the Cure 100
San Diego, CA 92121
USA

Phone

(858) 263-1222

Website

www.aspenneuroscience.com

Email Address

Not Recorded

Overview

Aspen is developing enabling technologies for patient-specific induced pluripotent stem cell-based therapies.

Profile

Social Media

Aspen Neuroscience Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Howard Federoff

Chief Financial Officer

Jay Sial

Chief Medical Officer

Edward Wirth

Chief Scientific Officer

Jeanne Loring

VP - Bus. Development

Naveen Krishnan

VP - Manufacturing

Thorsten Gorba

VP - R & D

Andres Bratt-Leal

Browse more venture capital transactions:

Prev: 11/19/2025: Cavela venture capital transaction
Next: 11/20/2025: Perelel venture capital transaction

Share this article

Where The Data Comes From

We report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary